Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Results: Treatment + Breast Cancer + Triple Negative + Stage 1 (2 results)
![Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer](https://www.facingourrisk.org/cdn-cgi/image/width=400,height=300,fit=contain,format=webp/uploads/assets/research/images/65007d29e6c76.jpg)
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.
![Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation](https://www.facingourrisk.org/cdn-cgi/image/width=400,height=300,fit=contain,format=webp/uploads/assets/research/images/6191ce90aedc5.jpg)
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.